Abion’s anticancer drug candidates, based on a companion diagnostics system, are tailored to each individual patient to achieve optimal therapeutic outcomes.
An anticancer drug candidate that targets c-Met alterations in driving various cancers (lungs, stomach, etc.).
In order to enhance clinical safety and efficacy, we are developing a therapeutic c-Met targeting agent that has eliminated complications (renal toxicity) related to first generation c-Met inhibitors together with a companion diagnostic system for patient selection as well as therapeutic and resistance monitoring.
Claudin-3 , an effective biomarker that can be utilized for diagnose and treatment of various cancers (ovarian, etc.).
ABN501 is a specific therapeutic antibody targeting ovarian cancer. In comparative studies with other anticancer agents, ABN501 shows superior cancer cell death in ovarian cancer cells. Currently we are developing expression cell lines for ABN501.
A fusion protein that targets cancer cells with antitumor activity of ABN101 (Interferon-beta).
Through in vivo efficacy tests, ABN201 have superior anticancer activity against cancer cells and improves toxicity levels of existing Antibody-Drug Conjugates (ADCs) and productivity via a fusion method compare to conjugation technique.
Abion is developing an Interferon-beta based biological drug for treatment of autoimmune diseases in the central nervous system with the goal of improving patient convenience at competitive prices.
The next generation drug for treatment of multiple sclerosis, ABN101 applies an additional glycosylation to Interferon-beta to enhance its productivity and stability.
ABN 101 will help minimize side effects and dosing frequency through improvement on solubility, pharmacokinetics and stability in comparison with marketed interferon-beta products.
| Target | Drug Type | Development Stage | Clinical Site | |||
|---|---|---|---|---|---|---|
| Discovery | Non-clinical | P-I | P-II | |||
| Relapsing-Remitting Multiple Sclerosis (RRMS) | Biobetter | EU | ||||
In efforts to expand and synergize Abion’s various pipelines, we are developing ABN701 vaccine against biological agents and ABN601, a drug that protects the immune system from acute radiation syndrome.
A vaccine that protects against infection from staphylococcal enterotoxin B (SEB).
Traditional SEB vaccines have often failed due to inability to remove the toxicity of the antigen, but ABN701 as a competitive drug has been shown to be non-toxic in various animal studies. ABN701 is also a major part of a health development project currently headed by South Korea’s Ministry of Health and Welfare (MOHW).
Innovative emergency medication that can dramatically increase survival rates by protecting the immune system from radiation exposure.
ABN601 is being introduced by Abion to prevent Acute Radiation Syndrome (ARS) in patients exposed to nuclear or medical radiation accidents. As there are currently no clinically approved drugs present in South Korea, ABN601 is expected to make a significant first impact as we progress to phase I clinical trial.
Anticancer Therapies
| Indication | Drug Type | Development Stage | Clinical Site | ||||
|---|---|---|---|---|---|---|---|
| Discovery | Non-clinical | P-I | P-II | ||||
| ABN401 | c-Met mutation (lung cancer and stomach cancer) | Small Molecule | AU, KR | ||||
| ABN501 | Pancarcinoma (breast cancer, ovarian cancer, etc.) |
Monoclonal Antibody | |||||
| ABN201 | TBD | Ab-cytokine fusion protein | |||||
Multiple Sclerosis
| Indication | Drug Type | Development Stage | Clinical Site | ||||
|---|---|---|---|---|---|---|---|
| Discovery | Non-clinical | P-I | P-II | ||||
| ABN101 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Biobetter | EU | ||||
Medical Countermeasures (MCM)
| Indication | Drug Type | Development Stage | Clinical Site | ||||
|---|---|---|---|---|---|---|---|
| Discovery | Non-clinical | P-I | P-II | ||||
| ABN701 | SEB (Superantigen Infection) | Vaccine | |||||
| ABN601 | Acute Radiation Syndrome (ARS) | Protein | KR | ||||